Weber-Levine Carly, Jiang Kelly, Al-Mistarehi Abdel-Hameed, Welland Jeremy, Hersh Andrew M, Horowitz Melanie Alfonzo, Davidar A Daniel, Sattari Shahab Aldin, Redmond Kristin J, Lee Sang H, Theodore Nicholas, Lubelski Daniel
Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Clin Neurol Neurosurg. 2025 Jan;248:108632. doi: 10.1016/j.clineuro.2024.108632. Epub 2024 Nov 7.
Traditional management of patients with metastatic epidural spinal cord compression (MESCC) consists of radiotherapy (RT) with or without surgical decompression. With extensive literature and the introduction of clinical frameworks, such as the neurologic, oncologic, mechanical, and systemic criteria and the epidural spinal cord compression scale, progress has been made in refining the appropriate treatment regimen. In this review, we analyze the existing literature to identify the consensus frameworks and the remaining gaps in clinical knowledge.
PubMed, Embase, Cochrane, Web of Science, Scopus, and ClinicalTrials.gov were queried in January 2023. Only articles comparing combination therapy (surgery plus RT) to RT alone and assessing neurological and/or survival outcomes in patients with MESCC were retained for full-text review.
Out of 2157 unique articles, 29 met inclusion criteria. The most common primary cancer locations included lung (n=1031, 20.0 %), breast (n=747, 14.5 %), and prostate (n=712, 13.8 %), and back pain was the most common symptom reported (n=1186/1622, 73.1 %). While baseline patient characteristics were not controlled between the different treatment regimens, the included studies demonstrated a median survival of 4.0 months (interquartile range [IQR] 3.0-6.1 months) in patients receiving RT alone compared to 7.7 months (IQR 6.3-11.1 months) in the cohort receiving combination therapy. Similarly, in patients undergoing RT alone, a median of 29.0 % (IQR 16.0-37.9 %) of patients experienced a neurologic improvement, compared to 38.0 % (IQR 31.5-64.4 %) of patients undergoing combination therapy.
In patients with high-grade, symptomatic MESCC, combination therapy with direct circumferential decompression is superior to RT alone in patients with less radiosensitive tumors. In patients with high-grade asymptomatic MESCC, RT alone can be pursued for patients with the most radiosensitive tumors, such as myeloma and lymphoma; however, more research is needed on the treatment of less radiosensitive tumors. A major grey area exists in the treatment of patients with intermediate grade epidural involvement.
转移性硬膜外脊髓压迫症(MESCC)患者的传统治疗包括放疗(RT),可联合或不联合手术减压。随着大量文献的出现以及临床框架的引入,如神经、肿瘤、机械和全身标准以及硬膜外脊髓压迫量表,在完善适当的治疗方案方面取得了进展。在本综述中,我们分析现有文献以确定共识框架和临床知识中仍存在的差距。
于2023年1月检索了PubMed、Embase、Cochrane、Web of Science、Scopus和ClinicalTrials.gov。仅保留比较联合治疗(手术加放疗)与单纯放疗并评估MESCC患者神经学和/或生存结果的文章进行全文审查。
在2157篇独特文章中,29篇符合纳入标准。最常见的原发癌部位包括肺癌(n = 1031,20.0%)、乳腺癌(n = 747,14.5%)和前列腺癌(n = 712,13.8%),背痛是最常报告的症状(n = 1186/1622,73.1%)。虽然不同治疗方案之间未对患者基线特征进行对照,但纳入研究表明,单纯接受放疗的患者中位生存期为4.0个月(四分位间距[IQR] 3.0 - 6.1个月),而接受联合治疗的队列中位生存期为7.7个月(IQR 6.3 - 11.1个月)。同样,单纯接受放疗的患者中,中位有29.0%(IQR 16.0 - 37.9%)的患者神经功能有改善,而接受联合治疗的患者这一比例为38.0%(IQR 31.5 - 64.4%)。
在高级别、有症状的MESCC患者中,对于放疗敏感性较低的肿瘤患者,直接环形减压联合治疗优于单纯放疗。在高级别无症状MESCC患者中,对于放疗敏感性最高的肿瘤患者,如骨髓瘤和淋巴瘤患者,可单纯进行放疗;然而,对于放疗敏感性较低的肿瘤的治疗,还需要更多研究。中级硬膜外受累患者的治疗存在一个主要的灰色地带。